AustraliaBreaking News

Imricor Medical Systems (ASX:IMR) has secured US regulatory clearances to expand its products across 250 paediatric hospitals.

Angela Ang, APAC MD of BitGo, a digital asset infrastructure company, believes that shifts from retail speculation to institutional investors drive demand for secure custody and compliant infrastructure. Her comments come on the back of bitcoin falling to a fresh 21-month low. She speaks with Haslinda Amin on "Insight with Haslinda Amin."

ATO launched a targeted assistance framework providing eligible fuel-affected businesses with three months of tax relief.

Alma Metals (ASX:ALM) acquired a 16-person exploration camp to expand operations at the Briggs Copper Project.

US President Donald Trump said negotiators had made progress in indirect talks with Iran to move past last week's tit-for-tat strikes and convert their interim truce into a lasting peace. Bloomberg's Stuart Livingstone-Wallace has the latest updates.

Intelligent Monitoring Group (ASX:IMB) agreed to buy ADT's United Kingdom residential security business for £180 million.

Imugene (ASX:IMU) announced a second complete response within 24 hours in its concurrent combination trial cohort.

Alex Yeh, Founder and CEO at GMI Cloud, discusses the company's business strategy and the outlook for the AI ecosystem. He speaks with Shery Ahn from the sidelines of the IVS2026 conference in Kyoto.

Takashi Sano, CIO at Mitsubishi UFJ Innovation Partners, discusses the investment opportunities in AI and the outlook for the innovation landscape. He speaks with Shery Ahn from the sidelines of the IVS2026 conference in Kyoto.

Clarey Zhu, Partner at Headline Growth, discusses the investment opportunities in Asia's tech sector, including AI infrastructure, deep tech and robotics. She speaks with Haidi Stroud-Watts from the sidelines of the IVS2026 conference in Kyoto.

Marc Luet, Head of Japan, Asia North & Australia and Banking at Citi, says the bank has seen the role of the yuan grow and is hopeful of obtaining a securities license in China. He speaks exclusively on "Bloomberg: The China Show."

Telix Pharmaceuticals (ASX:TLX) aligned with the US regulator to advance its Phase 3 trial after a 36-patient safety study.